Should Pneumococcal Serotype 3 Be Included in Serotype-Specific Immunoassays?

Linley, Ezra, Bell, Abigail, Gritzfeld, Jenna F and Borrow, Ray (2019) Should Pneumococcal Serotype 3 Be Included in Serotype-Specific Immunoassays? VACCINES, 7 (1). E4-.

Access the full-text of this item by clicking on the Open Access link.

Text
Should Pneumococcal Serotype 3 Be Included in Serotype-Specific Immunoassays?.pdf - Published version
Download (930kB) | Preview

Official URL: http://dx.doi.org/10.3390/vaccines7010004

Abstract

Since the introduction of the 13-valent pneumococcal conjugate vaccine, a number of studies have demonstrated the limited efficacy of the pneumococcal serotype 3 component of this vaccine. Evidence from seven countries (Denmark, France, Greece, Portugal, Sweden, UK, US) shows limited or no effectiveness of the 13-valent pneumococcal conjugate vaccine against serotype 3 invasive pneumococcal disease and carriage. The serotype 3 capsule has some unique characteristics that may serve to explain this lack of efficacy-capsular polysaccharide is abundantly expressed, leading to a greater thickness of capsule, and free capsular polysaccharide may be released during growth. The serotype 3 component of the Luminex multiplex assay demonstrates inferior inter-laboratory reproducibility than other components and results may not be reliable. This communication outlines this evidence and discusses whether it is necessary to include serotype 3 in the assay in the future.

Item Type:	Article
Uncontrolled Keywords:	Streptococcus pneumoniae, serotype 3, conjugate vaccine, multiplex, immunoassay
Depositing User:	Symplectic Admin
Date Deposited:	04 Jun 2019 10:00
Last Modified:	19 Jan 2023 00:41
DOI:	10.3390/vaccines7010004
Open Access URL:	https://doi.org/10.3390/vaccines7010004
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3044373